Results 31 to 40 of about 96 (70)

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Integrating gepants into clinical practice for the acute treatment of migraine

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 976-989, April 2026.
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Richard B. Lipton, David W. Dodick, Linda Davis, Stephanie J. Nahas, Peter J. Goadsby   +4 more
wiley   +1 more source

Case Report: Omadacycline in the Treatment of Community‐Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies

Clinical Case Reports, Volume 13, Issue 12, December 2025.
ABSTRACT Omadacycline, a novel once‐daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community‐acquired pneumonia (CAP) in adults. However, the safety and efficacy of omadacycline in younger children have not yet been established.
Ziqi Xu, Wen Pan, Hui Lei, Chen Dong, Biao Zou, Sainan Shu, Wenting Zhang   +6 more
wiley   +1 more source

Real-world pharmacovigilance of drug-related bone metabolism disorders: integrating FAERS and VigiAccess with a Bradford Hill-based causal plausibility assessment

Frontiers in Pharmacology
BackgroundMetabolic bone diseases (MBDs) are a group of conditions characterized by imbalanced bone remodeling, including osteoporosis, osteomalacia, and rickets.
Pei Liu, Pei Liu, Kun Zhao, Hong Zhang, Ming Qiang Liu, Jianlei Li, Yongqiang Sun   +6 more
doaj   +1 more source

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper

Allergy, Volume 80, Issue 11, Page 2973-2987, November 2025.
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini, Alla Nakonechna, Annick Barbaud, Sevim Bavbek, Gianfranco Calogiuri, Inmaculada Doña, Violeta Kvedariene, Jose Julio Laguna Martinez, Serena Liberati, Mauro Pagani, Antonino Romano   +10 more
wiley   +1 more source

Association between ranitidine use and thyroid cancer based on FAERS and VigiAccess databases

Discover Oncology
Purpose The potential carcinogenic risk of ranitidine has sparked widespread controversy, and its relationship with thyroid cancer remains unclear. This study aimed to evaluate the disproportionality signal for thyroid cancer reporting associated with ...
Qingli Shen, Zhonghua Fu, Zhengchao Xia, Yinhui Qin, Chenglong Zhao   +4 more
doaj   +1 more source

Serious Adverse Events: A Replicability and Validation Study of Naranjo Causality Assessment Tool in a Canadian Clinical Setting

Journal of Evaluation in Clinical Practice, Volume 31, Issue 3, April 2025.
ABSTRACT Rationale Patient safety has become a major concern in healthcare today as 5%–10% of patients experience serious adverse events (SAE) during their hospital stay. The causal assessment of SAE is the responsibility of healthcare professionals (HCP), who use their judgment or a standardize tool. Whether those two methods are replicable to provide
Pallavi Pradhan, Sonia Corbin, Shweta Todkar, Maude Lavallée, Isabelle Cloutier, Rosalie Darveau, Julie Méthot, Anick Bérard, Marie‐Eve Piché, Jacinthe Leclerc   +9 more
wiley   +1 more source

Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases

Orphanet Journal of Rare Diseases
Background Acute hepatic porphyria is a rare metabolic disorder characterized by life-threatening acute attacks and chronic neurological symptoms. Givosiran is an RNA interference therapeutic approved by the FDA in 2019 to treat AHP by inhibiting hepatic
Yinpeng Xu, Fang Li, Li Huang, Mei Zhang, Pengqiang Du   +4 more
doaj   +1 more source

Profiles of neuropsychiatric toxicity associated with different endocrine therapies for breast cancer: a global pharmacovigilance study based on FAERS and VigiAccess

Frontiers in Pharmacology
PurposeBreast cancer is the most common malignancy in women. Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients rely on endocrine therapy as their fundamental systemic treatment strategy.
Guoqiang Li, Mengqi Yang, Lei Zhang, Xin Li, Xiaoliang Wu, Feng Peng, Yajie Liu   +6 more
doaj   +1 more source

Thyroid and renal tumors in patients treated with long-term lithium: case series from a lithium clinic, review of the literature and international pharmacovigilance reports

International Journal of Bipolar Disorders, 2018
Background Cancer had never been considered as a relevant problem in patients treated with lithium until 2015, when a document published by the European Medicine Agency concluded that long-term use of lithium might induce renal tumors. A few months later,
Luca Ambrosiani, Claudia Pisanu, Arianna Deidda, Caterina Chillotti, Maria Erminia Stochino, Alberto Bocchetta   +5 more
doaj   +1 more source